Larimar under pressure as FDA puts clinical hold on CTI-1601 program

May 26, 2021 1:25 AM ETLarimar Therapeutics, Inc. (LRMR)LRMRBy: Mamta Mayani, SA News Editor
  • Larimar Therapeutics (NASDAQ:LRMR) slumps 45% in after-hours trading after announcing that the FDA has placed a clinical hold on the CTI-1601 clinical program and that the company will not be closing its previous private placement financing.
  • The clinical hold follows the mortalities which occurred at the highest dose levels in an ongoing 180-day non-human primate (NHP) toxicology study, previously reported in Phase 1 multiple ascending dose trial evaluating CTI-1601 as a treatment for Friedreich’s ataxia (FA).
  • CTI-1601 is a recombinant fusion protein intended to deliver human frataxin into the mitochondria of patients with FA who are unable to produce enough of this essential protein.
  • The FDA stated it needs a full study report from the ongoing NHP study and Larimar may not initiate additional clinical trials until the reports have been submitted or further notified by the Agency.
  • Larimar launched $95M private placement on May 21, to support the clinical development of CTI-1601.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.